Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.470
-0.030 (-2.03%)
Oct 6, 2026, 11:00 AM EDT - Market open

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $4.64M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $4.64M.

Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
111.69
Revenue / Employee
$30,526
Employees
152
Market Cap
507.72M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025---
Dec 31, 202422.00K-73.00K-76.84%
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Phathom Pharmaceuticals239.66M
Puma Biotechnology231.24M
REGENXBIO174.48M
Valneva SE163.30M
Oculis Holding AG1.45M
YD Bio1.24M
Neurogene925.00K
Altimmune31.00K
Revenue Rankings